Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Gatineau, Canada Clinical Trials

A listing of Gatineau, Canada clinical trials actively recruiting patients volunteers.

RESULTS

Found (425) clinical trials

A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease_

The name of this trial is MissionAD2. This 24-month treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 3 study in participants with Early Alzheimer's Disease (EAD) including mild cognitive impairment (MCI) due to AD/Prodromal AD and the early stages of mild AD will be conducted to evaluate the efficacy and safety ...

Phase

0.0 miles

Learn More »

Canadian CP Registry - Registre Canadien de la Paralysie C r brale

The Canadian Cerebral Palsy Registry is a multi-regional Canadian registry to identify potential risk factors related to pregnancy and interactions of the environment and genetics. The Registry provides researchers with the approximate number of children with cerebral palsy across Canada, and data in the Registry helps researchers explore reasons behind ...

Phase N/A

0.0 miles

Learn More »

Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis

One of the biggest problems facing prostate cancer patients and their treating physicians is who needs to be treated and when. Common clinical and pathological parameters are useful (PSA, Gleason score, etc.) but do not clearly predict who will benefit from treatment and who will fail. Genetic markers for tumor ...

Phase N/A

0.0 miles

Learn More »

Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults

This randomized, observer-blind, multicenter, Phase 3 lot consistency study will be conducted at multiple sites in Canada. The composition of the Quadrivalent VLP Influenza Vaccine used in this study includes two influenza A virus strains and two influenza B virus strains based on the 2016-2017 recommended strains for vaccination in ...

Phase

0.0 miles

Learn More »

221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with early AD. Secondary objectives are to assess the ...

Phase

0.81 miles

Learn More »

An Efficacy and Safety Study of JNJ-54861911 in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia

This is a randomized (study drug assigned by chance), double-blind (neither the researchers nor the participants know what treatment the participant is receiving), multi-center (more than one hospital or medical school team work on a medical research study), placebo-controlled, parallel-group study in participants who are asymptomatic and at risk for ...

Phase

0.81 miles

Learn More »

A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia

The main purpose of this study is to evaluate the efficacy of the study drug known as lanabecestat in participants with mild Alzheimer's disease (AD) dementia.

Phase

0.81 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of RO7105705 in Patients With Prodromal to Mild Alzheimer's Disease

This is a phase II, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of RO7105705 in participants with prodromal to mild Alzheimer's disease. An optional 96-week open-label extension period will be available to participants who complete the double-blind treatment period and who, in the judgment of the investigator, ...

Phase

0.81 miles

Learn More »

A Study of LY3002813 and LY3202626 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)

The purpose of this study is to evaluate the safety, tolerability and efficacy of LY3002813 alone and in combination with LY3202626 in early symptomatic Alzheimer's disease.

Phase

0.81 miles

Learn More »

Brain Imaging and Safety Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

The purpose of this study is to determine the safety and efficacy of TRx0237 8 mg/day in the treatment of subjects with mild Alzheimer's Disease compared to placebo.

Phase

0.81 miles

Learn More »